Kornimate/medical-research-clean huggingface dataset:
erlotinib with concurrent brain radiotherapy and secondary brain radiotherapy after recurrence with erlotinib in nsclc non-increased-intracranial-pressure symptomatic brain metastases

Conditions: Non-small-cell Lung Cancer; Brain Metastases

Summary: this project is aim to explore non-increased-intracranial-pressure symptomatic brain metastases of nsclc, and if the os of secondary brain radiotherapy after recurrence with erlotinib is better than erlotinib with concurrent brain radiotherapy. treatment group are treated with erlotinib until brain tumor progression, then gave brain radiotherapy, and continued to take erlotinib till extracranial lesions progression. control group are erlotinib with concurrent brain radiotherapy, and continued to take erlotinib after radiotherapy until recurrence or termination for other reasons.


Eligibility criteria:
inclusion criteria: 1. over the age of 18 years old; 2. tissue or cell pathological diagnosis of nsclc; 3. brain ct or mr validated bm; 4. non-increased-intracranial-pressure symptomatic bm; 5. haven't received tki target treatment; 6. haven't received brain radiotherapy; 7. patients in initial treatment should be detected egfr mutation; 8. expected survival more than 6 months; 9. kps no less than 70, or kps less than 70 caused by paralysis due to recent brain metastases; 10. liver and kidney function requirements: sgot/sgpt≦2.5 times of the upper limit, total bilirubin≦1.5 times of the upper limit, serum creatinine≦1.5 times of the upper limit; 11. routine blood test requirements: wbc≧3.0×109/l, ne≧1.8×109/l, plt≧90×109/l，no requirement for hb; 12. blood glucose requirements: within the normal range, diabetic patients are receiving treatment and their glucose was being controlled in a steady state; 13. female patients in childbearing age: hcg (-); 14. patients signed an inform consent. exclusion criteria: 1. those with erlotinib drug allergies; 2. those with mathematical understanding of the most simple life questions, such as "walking", those difficult for doctors to communicate; 3. those without guardians or families; 4. those with abnormal routine blood test, liver and kidney function, and blood glucose beyond the above boundaries and difficult to correcting for more than 2 weeks; 5. those with any unstable medical status (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction (within one year before treatment initiation), and severe arrhythmia, liver, kidney or metabolic disease requiring drug therapy); 6. those with any other disease, neurological or metabolic dysfunction, and physical examination or laboratory test results showed that the study drugs may increase the risk of treatment-related complications; 7. pregnant women.

Keywords: erlotinib brain radiotherapy nsclc brain metastases
methotrexate iontophoresis versus coal tar ointement in the treatment of primary palmer hyper hidrosis

Conditions: Hyperhidrosis; Iontophore

Summary: the purpose of the study is to compare the therapeutic effect of methotrexate iontophoresis versus coal tar ointment on the the treatment of primary palmer hyperhidrosis?

some researchers stated that hyperhidrosis can render the skin susceptible to infection because of the continuous dampness of the skin. the condition may become socially, psychologically and professionally debilitating. there are a lot of literatures concerned with studying the modalities used in the treatment of primary palmar hyperhidrosis, so this study will be conducted to compare between two of them and to show the best one for treating primary palmar hyperhidrosis.

Eligibility criteria:
inclusion criteria: * patient with primary palmar hyperhidrosis to extend that their palms are wet during most of the day (score 3 and 4 in the hyperhidrosis disease severity scale) was included in this study. * the palmer hyperhidrosis patient's age ranged from 15 to 35 years. * all patients will be examined by dermatologist before starting the study. exclusion criteria: the study excluded the following patients: * patients with medical conditions that associated with hyperhidrosis are excluded, these conditions include:- hyperthyroidism, diabetes mellitus, parkinsonism, spinal cord injury, brain damage, congestive heart failure, anxiety, alcoholism and menopause. * patients who received any treatment with a drug that was affecting sweating e.g. (thyroxin, anxiolytics.....) that is not stopped at least 4 weeks preceding the study. * patients with cardiac conditions such as arrhythmia, ischemic heart disease, low exercise tolerance, low respiratory reserve were excluded. * patients, who have a local wound, sever eczema and severe fungal infection of the palms to minimize risk of local burn. * patients who have sensory disorders. * female patients who are pregnant and lactating.
clinical efficacy and change of life quality through using the comprehensive behavioral intervention treatment for tics

Conditions: Tic Disorders

Summary: study on the clinical efficacy and change of life quality through using the comprehensive behavioral intervention treatment for tics (cbit)

this study tried to explore the clinical effect of comprehensive behavioral intervention therapy (cbit) on tic symptoms and the effect of improving the quality of life in children with tic disorders;explore the optimal treatment plan for tic disorder by comparing the clinical efficacy of cbit therapy, drug therapy, and psychosocial education; explore the feasibility of using quality of life as an evaluation index for functional recovery after tic disorder treatment;

Eligibility criteria:
inclusion criteria: * meets the diagnostic criteria for chronic tic disorder or tourette syndrome (ts) according to the fifth edition of the diagnostic and statistical manual of mental disorders (dsm-v), and has been diagnosed by two pediatric psychiatrists who are associate chief physicians or more; * the age ranged from 9 to 16 years old; * the total score of tic symptoms in the yale global tic severity scale (ygtss) is 13-30; * childrens webster's intelligence scale ≥ 85 * co-morbid adhd, but the drug treatment dose for adhd is stable (the drug has been stabilized for more than 6 weeks), or no drug has been taken at the beginning and during the stud exclusion criteria: * there are brain organic diseases, metabolic diseases, psychiatric disorders, drug-induced involuntary movement and other extrapyramidal lesions; * habit reversal training and other behavioral treatments for more than 4 weeks; * unwilling participants or disobedient subgroups in the study

Keywords: comprehensive behavioral intervention therapy drug therapy psychosocial education
reaching for equity in sleep apnea treatment (rest) study

Conditions: Sleep Apnea

Summary: this study will test a brief telephonic health coaching intervention to improve adherence to positive airway pressure therapy for treatment of obstructive sleep apnea.

the investigators will carry out a pilot study in which patients will be randomly assigned to receive health coaching or usual care. participants are english- and spanish-speaking patients from a county-based public health system who have received a positive airway pressure device for the treatment of sleep apnea. an unlicensed, trained health coach will call patients three times to resolve barriers to adherence. primary outcomes include both adherence measures collected by the device modem at baseline and 4 months, and patient-reported outcomes such as daytime sleepiness.

Eligibility criteria:
inclusion criteria: * english- or spanish-speaking * at least 18 years of age * had previously received a modem-enabled positive airway pressure device for the treatment of sleep apnea * not currently meeting medicare standards for adherence of at least 4 hours per night for at least 70% of the last 30 nights * received care from the san francisco general hospital sleep clinic exclusion criteria: * not english- or spanish-speaking * younger than 18 years * does not have phone number at which could be reached

Keywords: health coaching adherence to treatment health disparities
duloxetine in the treatment of melancholic depression

Conditions: Depressive Disorder, Major

Summary: the purpose of this study is to determine the optimal treatment strategy for mdd patients with melancholic features who do not respond to a standard daily dose. this study will allow investigators to mimic standard clinical practice. during the first 2 weeks of treatment, clinical evaluation of individual patient tolerability and efficacy will enable the dose of duloxetine to be adjusted. patients allocated to the flex group may have their daily dose of duloxetine adjusted in the attempt to elicit a clinical response.


Eligibility criteria:
inclusion criteria: * have a diagnosis of major depression with melancholic features, as defined by diagnostic and statistical manual of mental disorders fourth edition \[dsm-iv\] criteria. * experienced their first episode of major depression prior to age 50. * have a hamd17 total score of less than or equal to 20 at visits 1 and 2. * test negative for a urine pregnancy test at visit 1 (females). * agree to use medically acceptable and reliable means of birth control during the study, as determined by the investigator (females of child-bearing potential, not surgically sterilized and between menarche, and one year post-menopausal). exclusion criteria: * have any current and primary axis i mood disorder other than mdd, including, but not limited to, dysthymia, seasonal affective disorder or psychotic depression. * have a current episode of major depression that has failed to respond to two or more courses of antidepressant therapy or, in the judgment of the investigator, meets criteria for treatment-resistant depression * are at serious suicidal risk as determined by the investigator. * have a serious medical illness or clinically significant laboratory abnormalities that, in the judgment of the investigator, are likely to require medication/ intervention/ hospitalization during the course of the study. * had treatment with a monoamine oxidase inhibitor (maoi) within 14 days prior to visit 2 or potential need to use a maoi during the study or within 14 days of discontinuation of study drug.
"assessment of risk factors for depression treatment at a safety net clinic"

Conditions: Depression

Summary: the purpose of the study is to identify the barriers for effective treatment of depression, specifically whether modified chis scale is a valid tool for identifying the high risk patients for depression.

depression is a major illness that affects 10% of the population in a medical setting. it is often under diagnosed and under treated. it is an illness that can challenge a persons ability to perform even routine daily activities. review of the charts of patients diagnosed with depression showed 80% of the patients do not have follow up appointments. we wondered if modified chis scale could identify the risk factors for medication non-adherence. we hypothesised that modified chis scale an effective tool ,for identifying the compliance of patients with the antidepressant medication. we are conducting a retrospective cohort study at two of our residency based clinics by interviewing approximately 100 patients with chis scale and phq9 questionnaire on their office visits

Eligibility criteria:
inclusion criteria: * diagnosis of depression before april 15, 2009 * at least one visit since april 15, 2008 * age 18+ exclusion criteria: * none
effect of preoperative intervention with folic acid and vitamin b12 on postoperative neurobehavioral changes in children

Conditions: Delirium

Summary: comparison of preoperative folic acid and vitb12 intervention on postoperative delirium and long-term neurobehavioral changes in children under general anesthesia

folic acid, as a one-carbon unit transferase coenzyme, participates in the synthesis of purine and thymine, and is an important element of the nervous system. vitamin b12 participates in methyl conversion and folate metabolism in the body, promoting the conversion of 5-methyltetrahydrofolate to tetrahydrofolate. it has been reported that the lack of serum folic acid and b12 is associated with an increased risk of cognitive impairment. the explanation mechanism of the relationship between folic acid deficiency and cognitive dysfunction may be that folic acid deficiency leads to impaired central nervous system methylation, resulting in insufficient methyl synthesis of myelin sheaths, neurotransmitters, membrane phospholipids and deoxyribonucleic acid. our previous studies showed that preoperative folic acid supplementation can alleviate myelin damage and cognitive impairment in young rats caused by sevoflurane anesthesia. therefore, this study further explored the preoperative folic acid and coenzyme b12 supplementation for children's delirium and long-term neurobehavioral changes after general anesthesia.

Eligibility criteria:
inclusion criteria: 1. asa grade is ⅰ \~ ⅱ; 2. children aged 6 months to 2 years old; 3. it is planned to undergo head, neck and maxillofacial surgery under general anesthesia with anesthesia for less than 6 hours exclusion criteria: 1. children with a history of respiratory tract infection within 1 week; 2. children with congenital malformations such as congenital heart disease; 3. children with central nervous system diseases or mental disorders or mental disorders; 4. children with long-term use of sedative or analgesic drugs; 5. children with severe liver and kidney dysfunction; 6. received folic acid and vitb12 supplement treatment or taken related derivatives; 7. have taken drugs that affect absorption within the past month, such as sulfonamides, aspirin, etc .; 8. those who have participated in other relevant clinical research in the past 3 months; 9. children with stunting
evaluation of integrating miycn interventions in existing cgpp of pci

Conditions: Polio

Summary: the study has two arms; both experimental and control areas will receive standard interventions given under polio eradication program of pci. participants in the experimental arm receive additional interventions on nutrition (improve diet diversity in pregnant women and children of 6-23 months) for exact 12 months. the study includes awareness generation (regarding nutrition) through community mobilization, counseling and capacity building of community mobilization.

the experimental arm will receive the following interventions: 1. interpersonal communication (ipc) to reach target women (women in their 2nd or 3rd trimester of pregnancy and women with 6-23 months old child) to deliver messages on maternal nutrition package and complementary feeding through home visits made by community mobilization coordinator (cmc). 2. expanded community mobilization involving key influencers in family like husbands and mothers -in-law and community opinion leaders, religious leaders, village health sanitation and nutrition committee (vhsnc) members. the aims are to improve awareness, shift norms and perceptions, engage husbands and local opinion leaders to promote healthy behaviour practices related to maternal nutrition and complementary feeding. 3. strategic use of data to design a context-specific program and track the progress of the program with regards to impact on social norms and behaviors at household/community level and demonstrate the feasibility of integrating select miycn interventions in polio eradication platforms. 4. convergence: the convergence will mainly focus on three cs - maintain consistency, avoid conflict and enhance cooperation. this will aid in passing consistent miycn messages to the target community and ensure effective teamwork, collaboration and mutual support

Eligibility criteria:
inclusion criteria: for community * • women aged 15-49 years * willing and able to provide consent * women in 2nd and 3rd trimester of pregnancy and / or * women with children aged 6-23 months for cmc * women aged 18+ * currently appointed a cmc in a selected hra * willing and able to provide consent exclusion criteria: * women in first trimester of pregnancy * women whose index child (youngest child, between 6-23 months of age) is not her biological child * women whose index child is not currently living with the mother

Keywords: miycn -maternal infant young child nutrition cgpp - core group polio project a&t- alive and thrive pci- project concern international up- uttar pradesh vhsnc -village health, sanitation and nutrition committee cmc- community mobilization coordinator
effect of long-acting levodopa on obstructive sleep apnea in parkinson's disease

Conditions: Parkinson's Disease; Obstructive Sleep Apnea

Summary: this trial will assess whether long-acting levodopa taken at night improves obstructive sleep apnea (osa) in patients with parkinson's disease (pd), as compared with placebo.

participants with parkinson's disease and sleep apnea will take long-acting levodopa and placebo at bedtime for 2 weeks each, in a randomized order, with a 2-week washout period in-between. sleep studies will be done at the end of each period. the primary outcome will be the apnea-hypopnea index change from baseline to on-medication, comparing active medication to placebo. other outcomes will include other polysomnographic parameters such as oxygenation measures and sleep architecture variables, as well as the epworth sleepiness scale, the montreal cognitive assessment, the parkinson's disease sleep scale and the unified parkinson's disease rating scale. adverse events will be closely monitored.

Eligibility criteria:
inclusion criteria: 1. diagnosis of idiopathic pd consistent with the uk brain bank; 2. presence of osa on screening psg, as defined by an ahi ≥ 15/h (moderate to severe osa); 3. stable regimen of anti-pd medication for 4 weeks prior to entry into the study, and no planned change during the study exclusion criteria: 1. other major neurological disorder; 2. already taking long-acting levodopa (at any time of day); 3. taking short-acting levodopa at bedtime or during the night; 4. any contraindication to long-acting levodopa (see below); 5. severe levodopa induced dyskinesias; 6. already on or requiring treatment for restless legs syndrome ; 7. body mass index \>35 kg/m2; 8. intercurrent upper respiratory tract infection; 9. other known cause of osa (e.g. craniofacial malformation); 10. active treatment of osa (cpap, dental appliance or other), unless willing to stop treatment 2 weeks prior to start and during the duration of the study.
oral bioavailability of solid formulation of glpg1205 with and without food

Conditions: Healthy

Summary: the purpose of the study is to evaluate the amount of compound present in the blood (relative bioavailability) after a single oral administration of glpg1205 given as a capsule formulation in fasted versus fed conditions in male healthy subjects. also, the safety and tolerability of a single oral dose of glpg1205 given as a capsule formulation under fasted and fed conditions will be assessed.


Eligibility criteria:
inclusion criteria: * healthy male, age 18-50 years * bmi between 18-30 kg/m2 exclusion criteria: * any condition that might interfere with the procedures or tests in this study * drug or alcohol abuse * smoking
characterization of t cell responses following yellow fever virus vaccination in healthy adults

Conditions: Yellow Fever

Summary: the investigators at rockefeller university are doing this research to study how the immune system responds to viruses and other infectious agents by using the yellow fever 17d vaccine as a model. the yfv-17d vaccine is one of the safest and most effective vaccines known and has been used to vaccinate humans against yellow fever virus (yfv) infection since the 1930s. by studying how the human immune system responds to the yfv vaccine we hope to learn more about the normal functioning of the immune system so that it might be possible to design new, more effective types of vaccines to prevent important infectious diseases. the reason for doing this research is: currently there is very little information about which factors determine the effectiveness of the initial (primary) immune response to a foreign substance (antigen), such as a virus, that person may be exposed to. there is also very little known about what determines how effectively and for how long a person's immune system can react to the same antigen to prevent another infection. studies in animals have given us important information about how the immune systems of other animals behave upon initial or repeated exposure to antigens,but these topics have not been studied in detail in humans. the following hypotheses will be tested: * the magnitude of the initial expansion of t lymphocytes (the "clonal burst") specific for the infecting virus determines the level at which memory t cell responses are generated against the specific viral antigen and the duration of the memory t cell response generated in the body. * the majority of cd8 t cells generated after immunization are yellow fever specific and not "bystander activation" of non-specific cells.


Eligibility criteria:
inclusion criteria: 1. able to give informed consent. 2. age 18-45 years. 3. agrees not to take any vaccines within 30 days before or 30 days after yfv vaccination. exclusion criteria: 1. previously vaccinated with yellow fever vaccine. 2. a history of a medical condition resulting in impaired immunity. 3. use of immunosuppressive medications. 4. thymus gland dysfunction. 5. recipient of a blood product or immune globulin product within 42 days of the screening visit or 30 days after the yfv vaccination.

Keywords: yellow fever
effects of therapeutic tapping in primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: dysmenorrhea is more common among women of reproductive age, as it affects their quality of life and limit their daily activities and normal functioning. the estimates of dysmenorrhea from research conducted all around the world varied widely, from 20% to 90%. this study is planned to determine the effects of kt on clinical symptoms, qol and academic performance of students with primary dysmenorrhea.

literature suggested that kinesio tape technique, one of the effective physiotherapy technique, used for primary dysmenorrhea, to stimulate muscle movements, assist weak muscles (fascia and soft tissue), reduce discomfort and muscle cramps, facilitate proprioceptive input, boost lymph and blood flow, and relieve pain. this will be a randomized controlled trial, with three groups. participants in the experimental group will receive therapeutic tape on the sacral and suprapubic regions with the star shape and ligament with general physical therapy session. sham group (st) group will receive sham taping with general physical therapy session. participants in control group (cg) will receive only general physical therapy session. all groups will be assessed at baseline, at 8th week and 12th week for clinical symptoms, qol and academic performance.

Eligibility criteria:
inclusion criteria: * nulliparous women with primary dysmenorrhea * aged between 18 and 25 years. * having a regular menstruation cycle (28 ± 7 days) * severity of menstrual pain on vas: 4 and over in the previous 6 months. exclusion criteria: * secondary dysmenorrhea * childbirth, pelvic surgery, use of an intrauterine device, * malignant condition * chronic medication; antidepressants or oral contraceptives for at least 6 months prior to study * not volunteering to participate in the study * having an allergy to k.